Initiation of treatment for Waldenström’s macroglobulinemia: Practical guidance for starting treatment and managing complications

20 Jan 2021
Véronique Leblond, Meletios Dimopoulos, Ramón García-Sanz and Wojciech Jurczak outline the topic of treatment initiation for Waldenström’s macroglobulinemia, exploring treatment options, monitoring, and unmet needs.

Duration: 01:21:00
View full-length webinar

Speakers

Meletios Dimopoulos

Ramón García-Sanz

Wojciech Jurczak

Véronique Leblond

Related content

DISEASE EDUCATION

Managing toxicity with BTK inhibitors in Waldenström’s macroglobulinemia

Hematology • BeGenius Spotlight Series
FIND OUT MORE
DISEASE EDUCATION

The role of BTK inhibitors and genetic testing in Waldenström’s macroglobulinemia

Hematology • BeGenius Spotlight Series
FIND OUT MORE
DISEASE EDUCATION

ASH 2023 updates: Acquired mutations on BTK inhibitor-containing therapies

Hematology • BeGenius Spotlight Series
FIND OUT MORE

BeGenius Webinars

Explore educational content in blood cancers, delivered by global experts. Browse previous webinar recordings...

FIND OUT MORE

BeGenius Summits

Access on-demand discussions led by international experts and learn more about relevant topics in hematology.

FIND OUT MORE

BeGenius Patient Cases

Enhance your understanding of patient care with our interactive case studies on the diagnosis and treatment of...

FIND OUT MORE

BeGenius Spotlight Series

Stay up-to-date with recent developments and best-practice in your field with these bite-sized updates from...

FIND OUT MORE

BeGenius Steering Committee

Meet the team of international experts behind all BeGenius content and activities.

FIND OUT MORE

You are now leaving the website

This link is provided for information purposes only. You’ll be leaving beonemedaffairs.com and accessing a third-party website over which [BeOne Medicines | GmbH] has no control or influence.

This link will take you to a third-party website outside of beonemedaffairs.com.

[BeOne Medicines | GmbH] has no control over this website and makes no representations regarding its content or availability in your location. [BeOne Medicines | GmbH] declines any responsibility for third-party information, data usage policies, or personal data processing.

By proceeding, you acknowledge that you are part of the intended audience of the third-party website and confirm your compliance with applicable laws.

Do you want to leave beonemedaffairs.com

You are now leaving the the website beonemedaffairs.com and entering another BeOne website with different terms of use. Information included on this website may not be specific to your country. Click Continue to proceed